{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:57:45Z","timestamp":1791896265322,"version":"4.3.4"},"reference-count":324,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma provide multidisciplinary diagnostic workup, staging, and treatment recommendations for resectable, borderline resectable, unresectable, locally advanced, and metastatic disease. This article summarizes the studies and Panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pancreatic Adenocarcinoma.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0046","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:28Z","timestamp":1791895228000},"source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"Andrew H.","family":"Ko","sequence":"first","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokenge P.","family":"Malafa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Aguilera","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olca","family":"Basturk","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana B.","family":"Cardin","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Gabriela","family":"Chiorean","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Christensen","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Czito","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Del","family":"Chiaro","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Dillhoff","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Donahue","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Fountzilas","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Hardacre","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Klute","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kunstman","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian-Huat","family":"Lim","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"LoConte","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashiq","family":"Masood","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassadie","family":"Moravek","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Action Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Nakakura","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol K.","family":"Narang","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Nardo","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Obando","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio M.","family":"Polanco","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Poultsides","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Reddy","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Scaife","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardaman","family":"Shergill","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Vollmer","sequence":"additional","affiliation":[{"name":"Abramson Cancer Centerat the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Wolpin","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"McCullough","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney L.","family":"Roth","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swathi","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel RL","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Cancer statistics, 2026. CA Cancer J Clin 2026;76:e70043."},{"key":"B2","series-title":"N Engl J Med","first-page":"1200","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos JP","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200\u20131210."},{"key":"B3","series-title":"JAMA","first-page":"1073","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos JP","year":"2010","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073\u20131081."},{"key":"B4","series-title":"JAMA","first-page":"267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle H","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267\u2013277."},{"key":"B5","series-title":"JAMA","first-page":"1019","article-title":"Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial","volume":"299","author":"Regine WF","year":"2008","unstructured":"Regine WF, Winter KA, Abrams RA, Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019\u20131026."},{"key":"B6","series-title":"Ann Surg Oncol","first-page":"1201","article-title":"Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival","volume":"13","author":"Massucco P","year":"2006","unstructured":"Massucco P, Capussotti L, Magnino A, Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006;13:1201\u20131208."},{"key":"B7","series-title":"Semin Radiat Oncol","first-page":"226","article-title":"Radiochemotherapy in the management of pancreatic cancer\u2013part I: neoadjuvant treatment","volume":"15","author":"Mornex F","year":"2005","unstructured":"Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer\u2013part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226\u2013234."},{"key":"B8","series-title":"World J Gastroenterol","first-page":"4883","article-title":"Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?","volume":"16","author":"Reni M.","year":"2010","unstructured":"Reni M. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol 2010;16:4883\u20134887."},{"key":"B9","series-title":"Ann Surg Oncol","first-page":"1035","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary GR","year":"2006","unstructured":"Varadhachary GR, Tamm EP, Abbruzzese JL, Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035\u20131046."},{"key":"B10","series-title":"Ann Surg Oncol","first-page":"758","article-title":"Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas","volume":"8","author":"White RR","year":"2001","unstructured":"White RR, Hurwitz HI, Morse MA, Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758\u2013765."},{"key":"B11","series-title":"HPB (Oxford)","first-page":"574","article-title":"Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis","volume":"15","author":"Araujo RL","year":"2013","unstructured":"Araujo RL, Gaujoux S, Huguet F, Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford) 2013;15:574\u2013580."},{"key":"B12","series-title":"Oncologist","first-page":"192","article-title":"Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?","volume":"17","author":"Lim KH","year":"2012","unstructured":"Lim KH, Chung E, Khan A, Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist 2012;17:192\u2013200."},{"key":"B13","series-title":"Cancer","first-page":"2671","article-title":"Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma","volume":"122","author":"Cloyd JM","year":"2016","unstructured":"Cloyd JM, Crane CH, Koay EJ, Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 2016;122:2671\u20132679."},{"key":"B14","series-title":"Clin Cancer Res","first-page":"2777","article-title":"Presurgical ablative radiation is associated with local control and immune response in pancreatic cancer","volume":"31","author":"Leung PQ","year":"2025","unstructured":"Leung PQ, Elghonaimy EA, Elamir AM, Presurgical ablative radiation is associated with local control and immune response in pancreatic cancer. Clin Cancer Res 2025;31:2777\u20132792."},{"key":"B15","series-title":"Ann Oncol","first-page":"1387","article-title":"Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review","volume":"20","author":"Le Scodan R","year":"2009","unstructured":"Le Scodan R, Mornex F, Girard N, Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009;20:1387\u20131396."},{"key":"B16","series-title":"Ann Surg Oncol","first-page":"2456","article-title":"Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma without increasing perioperative toxicity","volume":"29","author":"Hill CS","year":"2022","unstructured":"Hill CS, Rosati LM, Hu C, Neoadjuvant stereotactic body radiotherapy after upfront chemotherapy improves pathologic outcomes compared with chemotherapy alone for patients with borderline resectable or locally advanced pancreatic adenocarcinoma without increasing perioperative toxicity. Ann Surg Oncol 2022;29:2456\u20132468."},{"key":"B17","series-title":"Radiother Oncol","first-page":"110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong MD","year":"2024","unstructured":"Chuong MD, Lee P, Low DA, Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study. Radiother Oncol 2024;191:110064."},{"key":"B18","series-title":"J Radiat Oncol","first-page":"413","article-title":"Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor\u2013vessel relationships","volume":"2","author":"Dholakia AS","year":"2013","unstructured":"Dholakia AS, Hacker-Prietz A, Wild AT, Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor\u2013vessel relationships. J Radiat Oncol 2013;2:413\u2013425."},{"key":"B19","series-title":"Cancer","first-page":"5749","article-title":"Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators","volume":"118","author":"Katz MH","year":"2012","unstructured":"Katz MH, Fleming JB, Bhosale P, Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 2012;118:5749\u20135756."},{"key":"B20","series-title":"AJR Am J Roentgenol","first-page":"570","article-title":"Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert panel narrative review","volume":"218","author":"Soloff EV","year":"2022","unstructured":"Soloff EV, Al-Hawary MM, Desser TS, Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert panel narrative review. AJR Am J Roentgenol 2022;218:570\u2013581."},{"key":"B21","series-title":"Diagn Interv Imaging","first-page":"1225","article-title":"Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer","volume":"97","author":"Cassinotto C","year":"2016","unstructured":"Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging 2016;97:1225\u20131232."},{"key":"B22","series-title":"Cancer","first-page":"2692","article-title":"A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer","volume":"119","author":"Kim EJ","year":"2013","unstructured":"Kim EJ, Ben-Josef E, Herman JM, A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692\u20132700."},{"key":"B23","series-title":"J Surg Oncol","first-page":"587","article-title":"Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma","volume":"101","author":"Landry J","year":"2010","unstructured":"Landry J, Catalano PJ, Staley C, Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010;101:587\u2013592."},{"key":"B24","series-title":"Ann Surg Oncol","first-page":"3521","article-title":"Phase I\/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer","volume":"15","author":"Marti JL","year":"2008","unstructured":"Marti JL, Hochster HS, Hiotis SP, Phase I\/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008;15:3521\u20133531."},{"key":"B25","series-title":"JAMA Surg","first-page":"e161137","article-title":"Preoperative modified FOLFIRINOX Treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz MH","year":"2016","unstructured":"Katz MH, Shi Q, Ahmad SA, Preoperative modified FOLFIRINOX Treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101. JAMA Surg 2016;151:e161137."},{"key":"B26","series-title":"HPB (Oxford)","first-page":"73","article-title":"Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer","volume":"12","author":"McClaine RJ","year":"2010","unstructured":"McClaine RJ, Lowy AM, Sussman JJ, Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) 2010;12:73\u201379."},{"key":"B27","series-title":"Ann Surg Oncol","first-page":"619","article-title":"Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer","volume":"18","author":"Stokes JB","year":"2011","unstructured":"Stokes JB, Nolan NJ, Stelow EB, Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011;18:619\u2013627."},{"key":"B28","series-title":"J Gastrointest Surg","first-page":"2059","article-title":"A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer","volume":"15","author":"Laurence JM","year":"2011","unstructured":"Laurence JM, Tran PD, Morarji K, A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 2011;15:2059\u20132069."},{"key":"B29","series-title":"Oncologist","first-page":"266","article-title":"Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?","volume":"19","author":"Christians KK","year":"2014","unstructured":"Christians KK, Tsai S, Mahmoud A, Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19:266\u2013274."},{"key":"B30","series-title":"Acta Oncol","first-page":"1231","article-title":"Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma","volume":"52","author":"Tinchon C","year":"2013","unstructured":"Tinchon C, Hubmann E, Pichler A, Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 2013;52:1231\u20131233."},{"key":"B31","series-title":"J Surg Oncol","first-page":"587","article-title":"Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?","volume":"114","author":"Kim SS","year":"2016","unstructured":"Kim SS, Nakakura EK, Wang ZJ, Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol 2016;114:587\u2013596."},{"key":"B32","series-title":"Lancet Oncol","first-page":"1346","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen QP","year":"2025","unstructured":"Janssen QP, van Dam JL, van Bekkum ML, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol 2025;26:1346\u20131356."},{"key":"B33","series-title":"JAMA Oncol","first-page":"1263","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz MHG","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial. JAMA Oncol 2022;8:1263\u20131270."},{"key":"B34","series-title":"Acta Oncol","first-page":"979","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon EA","year":"2015","unstructured":"Mellon EA, Hoffe SE, Springett GM, Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015;54:979\u2013985."},{"key":"B35","series-title":"Expert Rev Anticancer Ther","first-page":"1461","article-title":"Stereotactic body radiation therapy in pancreatic cancer: the new frontier","volume":"14","author":"Moningi S","year":"2014","unstructured":"Moningi S, Marciscano AE, Rosati LM, Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther 2014;14:1461\u20131475."},{"key":"B36","series-title":"J Clin Oncol","first-page":"515","article-title":"Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: A propensity score matched analysis","volume":"35","author":"Mokdad AA","year":"2017","unstructured":"Mokdad AA, Minter RM, Zhu H, Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: A propensity score matched analysis. J Clin Oncol 2017;35:515\u2013522."},{"key":"B37","series-title":"Cancer","first-page":"2044","article-title":"Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma","volume":"117","author":"Artinyan A","year":"2011","unstructured":"Artinyan A, Anaya DA, McKenzie S, Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:2044\u20132049."},{"key":"B38","series-title":"J Clin Oncol","first-page":"3496","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans DB","year":"2008","unstructured":"Evans DB, Varadhachary GR, Crane CH, Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3496\u20133502."},{"key":"B39","series-title":"J Clin Oncol","first-page":"317","article-title":"Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study","volume":"16","author":"Hoffman JP","year":"1998","unstructured":"Hoffman JP, Lipsitz S, Pisansky T, Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317\u2013323."},{"key":"B40","series-title":"Ann Surg Oncol","first-page":"2088","article-title":"A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin","volume":"14","author":"Palmer DH","year":"2007","unstructured":"Palmer DH, Stocken DD, Hewitt H, A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:2088\u20132096."},{"key":"B41","series-title":"J Clin Oncol","first-page":"928","article-title":"Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"15","author":"Spitz FR","year":"1997","unstructured":"Spitz FR, Abbruzzese JL, Lee JE, Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928\u2013937."},{"key":"B42","series-title":"Ann Surg Oncol","first-page":"150","article-title":"A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma","volume":"13","author":"Talamonti MS","year":"2006","unstructured":"Talamonti MS, Small W, Jr., Mulcahy MF, A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150\u2013158."},{"key":"B43","series-title":"Ann Surg Oncol","first-page":"123","article-title":"Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration","volume":"8","author":"Breslin TM","year":"2001","unstructured":"Breslin TM, Hess KR, Harbison DB, Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123\u2013132."},{"key":"B44","series-title":"Surgery","first-page":"547","article-title":"Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma","volume":"150","author":"Takahashi H","year":"2011","unstructured":"Takahashi H, Ogawa H, Ohigashi H, Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery 2011;150:547\u2013556."},{"key":"B45","series-title":"J Gastrointest Surg","first-page":"121","article-title":"Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas","volume":"5","author":"Pingpank JF","year":"2001","unstructured":"Pingpank JF, Hoffman JP, Ross EA, Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121\u2013130."},{"key":"B46","series-title":"Strahlenther Onkol","first-page":"7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher H","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H, Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol 2015;191:7\u201316."},{"key":"B47","series-title":"Ann Surg","first-page":"481","article-title":"Surgical outcome results from SWOG S1505: A randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad SA","year":"2020","unstructured":"Ahmad SA, Duong M, Sohal DPS, Surgical outcome results from SWOG S1505: A randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg 2020;272:481\u2013486."},{"key":"B48","series-title":"JAMA Oncol","first-page":"421","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial","volume":"7","author":"Sohal DPS","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial. JAMA Oncol 2021;7:421\u2013427."},{"key":"B49","series-title":"J Clin Oncol","first-page":"1220","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial","volume":"40","author":"Versteijne E","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the dutch randomized PREOPANC trial. J Clin Oncol 2022;40:1220\u20131230."},{"key":"B50","series-title":"Lancet","first-page":"2945","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 x 2 factorial phase 3 trial","volume":"406","author":"Reni M","year":"2026","unstructured":"Reni M, Macchini M, Orsi G, Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 x 2 factorial phase 3 trial. Lancet 2026;406:2945\u20132956."},{"key":"B51","series-title":"Ann Surg Oncol","first-page":"2787","article-title":"Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design","volume":"20","author":"Katz MH","year":"2013","unstructured":"Katz MH, Marsh R, Herman JM, Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013;20:2787\u20132795."},{"key":"B52","series-title":"Ann Surg Oncol","first-page":"3712","article-title":"Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?","volume":"20","author":"Varadhachary GR","year":"2013","unstructured":"Varadhachary GR, Evans DB. Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'? Ann Surg Oncol 2013;20:3712\u20133714."},{"key":"B53","series-title":"Ann Surg Oncol","first-page":"1579","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz R","year":"2022","unstructured":"Alva-Ruiz R, Yohanathan L, Yonkus JA, Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer. Ann Surg Oncol 2022;29:1579\u20131591."},{"key":"B54","series-title":"Pancreas","first-page":"837","article-title":"Benefit of gemcitabine\/nab-paclitaxel rescue of patients with borderline resectable or locally advanced pancreatic adenocarcinoma after early failure of FOLFIRINOX","volume":"48","author":"Vreeland TJ","year":"2019","unstructured":"Vreeland TJ, McAllister F, Javadi S, Benefit of gemcitabine\/nab-paclitaxel rescue of patients with borderline resectable or locally advanced pancreatic adenocarcinoma after early failure of FOLFIRINOX. Pancreas 2019;48:837\u2013843."},{"key":"B55","series-title":"Lancet","first-page":"1049","article-title":"Pancreatic cancer","volume":"363","author":"Li D","year":"2004","unstructured":"Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049\u20131057."},{"key":"B56","series-title":"Cancer","first-page":"2284","article-title":"Cancer of the pancreas. 50 years of surgery","volume":"60","author":"Gudjonsson B.","year":"1987","unstructured":"Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284\u20132303."},{"key":"B57","series-title":"Ann Surg","first-page":"358","article-title":"Improved hospital morbidity, mortality, and survival after the Whipple procedure","volume":"206","author":"Crist DW","year":"1987","unstructured":"Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358\u2013365."},{"key":"B58","series-title":"Lancet","first-page":"1011","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos JP","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011\u20131024."},{"key":"B59","series-title":"JAMA Oncol","first-page":"1571","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy T","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial. JAMA Oncol 2022;8:1571\u20131578."},{"key":"B60","series-title":"J Clin Oncol","first-page":"2007","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero MA","year":"2023","unstructured":"Tempero MA, Pelzer U, O\u2019Reilly EM, Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial. J Clin Oncol 2023;41:2007\u20132019."},{"key":"B61","series-title":"J Clin Oncol","first-page":"1240","article-title":"Pancreatic adenocarcinoma: Long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial","volume":"43","author":"Palmer DH","year":"2025","unstructured":"Palmer DH, Jackson R, Springfeld C, Pancreatic adenocarcinoma: Long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial. J Clin Oncol 2025;43:1240\u20131253."},{"key":"B62","series-title":"Ann Surg","first-page":"852","article-title":"Validation of the PANAMA score for survival and benefit of adjuvant therapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX","volume":"281","author":"Rompen IF","year":"2025","unstructured":"Rompen IF, Stoop TF, van Roessel S, Validation of the PANAMA score for survival and benefit of adjuvant therapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX. Ann Surg 2025;281:852\u2013860."},{"key":"B63","series-title":"JAMA Oncol","first-page":"316","article-title":"Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy","volume":"9","author":"Sugawara T","year":"2023","unstructured":"Sugawara T, Rodriguez Franco S, Sherman S, Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol 2023;9:316\u2013323."},{"key":"B64","series-title":"J Surg Oncol","first-page":"151","article-title":"DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma","volume":"67","author":"Allison DC","year":"1998","unstructured":"Allison DC, Piantadosi S, Hruban RH, DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151\u2013159."},{"key":"B65","series-title":"J Gastrointest Surg","first-page":"1338","article-title":"A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon\u2019s contribution to long-term survival in pancreatic cancer","volume":"10","author":"Howard TJ","year":"2006","unstructured":"Howard TJ, Krug JE, Yu J, A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon\u2019s contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10:1338\u20131345."},{"key":"B66","series-title":"J Gastrointest Surg","first-page":"567","article-title":"Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators","volume":"4","author":"Sohn TA","year":"2000","unstructured":"Sohn TA, Yeo CJ, Cameron JL, Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567\u2013579."},{"key":"B67","series-title":"Pancreatology","first-page":"1037","article-title":"Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review","volume":"16","author":"Petrucciani N","year":"2016","unstructured":"Petrucciani N, Nigri G, Debs T, Frozen section analysis of the pancreatic margin during pancreaticoduodenectomy for cancer: Does extending the resection to obtain a secondary R0 provide a survival benefit? Results of a systematic review. Pancreatology 2016;16:1037\u20131043."},{"key":"B68","series-title":"Ann Surg Oncol","first-page":"1751","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement","volume":"16","author":"Abrams RA","year":"2009","unstructured":"Abrams RA, Lowy AM, O\u2019Reilly EM, Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009;16:1751\u20131756."},{"key":"B69","series-title":"Ann Surg Oncol","first-page":"1727","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement","volume":"16","author":"Callery MP","year":"2009","unstructured":"Callery MP, Chang KJ, Fishman EK, Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:1727\u20131733."},{"key":"B70","series-title":"Surgery","first-page":"977","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn M","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2014;155:977\u2013988."},{"key":"B71","series-title":"World J Surg","first-page":"164","article-title":"Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections","volume":"23","author":"Bottger TC","year":"1999","unstructured":"Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg 1999;23:164\u2013171; discussion 171\u2013162."},{"key":"B72","series-title":"Am J Surg","first-page":"480","article-title":"Considerations that lower pancreatoduodenectomy mortality","volume":"133","author":"Braasch JW","year":"1977","unstructured":"Braasch JW, Gray BN. Considerations that lower pancreatoduodenectomy mortality. Am J Surg 1977;133:480\u2013484."},{"key":"B73","series-title":"Ann Surg","first-page":"432","article-title":"Pancreaticoduodenal resection. Surgical experience and evaluation of risk factors in 103 patients","volume":"199","author":"Lerut JP","year":"1984","unstructured":"Lerut JP, Gianello PR, Otte JB, Kestens PJ. Pancreaticoduodenal resection. Surgical experience and evaluation of risk factors in 103 patients. Ann Surg 1984;199:432\u2013437."},{"key":"B74","series-title":"Lancet","first-page":"896","article-title":"Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial","volume":"2","author":"Hatfield AR","year":"1982","unstructured":"Hatfield AR, Tobias R, Terblanche J, Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982;2:896\u2013899."},{"key":"B75","series-title":"Br J Surg","first-page":"1195","article-title":"Preoperative endoscopic drainage for malignant obstructive jaundice","volume":"81","author":"Lai EC","year":"1994","unstructured":"Lai EC, Mok FP, Fan ST, Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994;81:1195\u20131198."},{"key":"B76","series-title":"Br J Surg","first-page":"371","article-title":"Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial","volume":"71","author":"McPherson GA","year":"1984","unstructured":"McPherson GA, Benjamin IS, Hodgson HJ, Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984;71:371\u2013375."},{"key":"B77","series-title":"Am J Surg","first-page":"727","article-title":"Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy","volume":"148","author":"Thomas JH","year":"1984","unstructured":"Thomas JH, Connor CS, Pierce GE, Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy. Am J Surg 1984;148:727\u2013731."},{"key":"B78","series-title":"Am J Gastroenterol","first-page":"1168","article-title":"Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy","volume":"108","author":"Cavell LK","year":"2013","unstructured":"Cavell LK, Allen PJ, Vinoya C, Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. Am J Gastroenterol 2013;108:1168\u20131173."},{"key":"B79","series-title":"N Engl J Med","first-page":"129","article-title":"Preoperative biliary drainage for cancer of the head of the pancreas","volume":"362","author":"van der Gaag NA","year":"2010","unstructured":"van der Gaag NA, Rauws EA, van Eijck CH, Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010;362:129\u2013137."},{"key":"B80","series-title":"Gastrointest Endosc","first-page":"67","article-title":"Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study","volume":"76","author":"Aadam AA","year":"2012","unstructured":"Aadam AA, Evans DB, Khan A, Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc 2012;76:67\u201375."},{"key":"B81","series-title":"J Gastrointest Surg","first-page":"1094","article-title":"Pancreaticoduodenectomy after placement of endobiliary metal stents","volume":"9","author":"Mullen JT","year":"2005","unstructured":"Mullen JT, Lee JH, Gomez HF, Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005;9:1094\u20131104; discussion 1104\u20131095."},{"key":"B82","series-title":"Oncology","first-page":"1335","article-title":"The war on pancreatic cancer: are we gaining ground?","volume":"24","author":"Varadhachary GR","year":"2011","unstructured":"Varadhachary GR, Wolff RA. The war on pancreatic cancer: are we gaining ground? Oncology 2011;24:1335\u20131336."},{"key":"B83","series-title":"Ann Surg","first-page":"47","article-title":"Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients","volume":"234","author":"Pisters PW","year":"2001","unstructured":"Pisters PW, Hudec WA, Hess KR, Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 2001;234:47\u201355."},{"key":"B84","series-title":"J Clin Oncol","first-page":"3487","article-title":"Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Varadhachary GR","year":"2008","unstructured":"Varadhachary GR, Wolff RA, Crane CH, Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487\u20133495."},{"key":"B85","series-title":"Cardiovasc Intervent Radiol","first-page":"352","article-title":"Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE\/FEP-covered versus uncovered nitinol biliary stents","volume":"34","author":"Krokidis M","year":"2011","unstructured":"Krokidis M, Fanelli F, Orgera G, Percutaneous palliation of pancreatic head cancer: randomized comparison of ePTFE\/FEP-covered versus uncovered nitinol biliary stents. Cardiovasc Intervent Radiol 2011;34:352\u2013361."},{"key":"B86","series-title":"Gastrointest Endosc","first-page":"915","article-title":"Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study","volume":"72","author":"Kullman E","year":"2010","unstructured":"Kullman E, Frozanpor F, Soderlund C, Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010;72:915\u2013923."},{"key":"B87","series-title":"Dig Dis Sci","first-page":"516","article-title":"Management of complications associated with partially covered biliary metal stents","volume":"55","author":"Ho H","year":"2010","unstructured":"Ho H, Mahajan A, Gosain S, Management of complications associated with partially covered biliary metal stents. Dig Dis Sci 2010;55:516\u2013522."},{"key":"B88","series-title":"Gastrointest Endosc","first-page":"907","article-title":"A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction","volume":"72","author":"Telford JJ","year":"2010","unstructured":"Telford JJ, Carr-Locke DL, Baron TH, A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010;72:907\u2013914."},{"key":"B89","series-title":"Gastrointest Endosc","first-page":"1003","article-title":"Biliary and pancreatic stents","volume":"97","author":"Han S","year":"2023","unstructured":"Han S, Obando JV, Bhatt A, Biliary and pancreatic stents. Gastrointest Endosc 2023;97:1003\u20131004."},{"key":"B90","series-title":"J Gastroenterol Hepatol","first-page":"234","article-title":"Gastrointestinal and biliary stents","volume":"25","author":"Chun HJ","year":"2010","unstructured":"Chun HJ, Kim ES, Hyun JJ, Gastrointestinal and biliary stents. J Gastroenterol Hepatol 2010;25:234\u2013243."},{"key":"B91","series-title":"Ann Surg Oncol","first-page":"1335","article-title":"Laparoscopic pancreatoduodenectomy: a review of 285 published cases","volume":"18","author":"Gumbs AA","year":"2011","unstructured":"Gumbs AA, Rodriguez Rivera AM, Milone L, Hoffman JP. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol 2011;18:1335\u20131341."},{"key":"B92","series-title":"Ann Surg","first-page":"1048","article-title":"Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis","volume":"255","author":"Venkat R","year":"2012","unstructured":"Venkat R, Edil BH, Schulick RD, Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012;255:1048\u20131059."},{"key":"B93","series-title":"Minerva Chir","first-page":"151","article-title":"Surgical techniques for pancreatic cancer","volume":"59","author":"Nakeeb A","year":"2004","unstructured":"Nakeeb A, Lillemoe KD, Grosfeld JL. Surgical techniques for pancreatic cancer. Minerva Chir 2004;59:151\u2013163."},{"key":"B94","series-title":"Curr Probl Cancer","first-page":"176","article-title":"Pancreatic cancer","volume":"26","author":"Yeo TP","year":"2002","unstructured":"Yeo TP, Hruban RH, Leach SD, Pancreatic cancer. Curr Probl Cancer 2002;26:176\u2013275."},{"key":"B95","series-title":"Surg Radiol Anat","first-page":"13","article-title":"Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study","volume":"31","author":"Baque P","year":"2009","unstructured":"Baque P, Iannelli A, Delotte J, Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surg Radiol Anat 2009;31:13\u201317."},{"key":"B96","series-title":"Am J Surg","first-page":"606","article-title":"Novel applications of endo GIA linear staplers during pancreaticoduodenectomy and total pancreatectomy","volume":"185","author":"Evans DB","year":"2003","unstructured":"Evans DB, Pisters PW. Novel applications of endo GIA linear staplers during pancreaticoduodenectomy and total pancreatectomy. Am J Surg 2003;185:606\u2013607."},{"key":"B97","series-title":"Ann Surg","first-page":"342","article-title":"Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection?","volume":"224","author":"Harrison LE","year":"1996","unstructured":"Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996;224:342\u2013347; discussion 347\u2013349."},{"key":"B98","series-title":"J Gastrointest Surg","first-page":"1106","article-title":"Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection","volume":"10","author":"Riediger H","year":"2006","unstructured":"Riediger H, Makowiec F, Fischer E, Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg 2006;10:1106\u20131115."},{"key":"B99","series-title":"J Gastrointest Surg","first-page":"935","article-title":"Pancreaticoduodenectomy with vascular resection: margin status and survival duration","volume":"8","author":"Tseng JF","year":"2004","unstructured":"Tseng JF, Raut CP, Lee JE, Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935\u2013949; discussion 949\u2013950."},{"key":"B100","series-title":"Ann Surg Oncol","first-page":"1399","article-title":"Survival after pancreatectomy with major arterial resection and reconstruction","volume":"15","author":"Stitzenberg KB","year":"2008","unstructured":"Stitzenberg KB, Watson JC, Roberts A, Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 2008;15:1399\u20131406."},{"key":"B101","series-title":"JAMA Surg","first-page":"331","article-title":"Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients","volume":"148","author":"Worni M","year":"2013","unstructured":"Worni M, Castleberry AW, Clary BM, Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg 2013;148:331\u2013338."},{"key":"B102","series-title":"Ann Surg","first-page":"882","article-title":"Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis","volume":"254","author":"Mollberg N","year":"2011","unstructured":"Mollberg N, Rahbari NN, Koch M, Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 2011;254:882\u2013893."},{"key":"B103","series-title":"J Gastrointest Surg","first-page":"946","article-title":"Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?","volume":"7","author":"Shoup M","year":"2003","unstructured":"Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg 2003;7:946\u2013952; discussion 952."},{"key":"B104","series-title":"J Am Coll Surg","first-page":"244","article-title":"Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins","volume":"204","author":"Strasberg SM","year":"2007","unstructured":"Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg 2007;204:244\u2013249."},{"key":"B105","series-title":"J Gastrointest Surg","first-page":"922","article-title":"Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas","volume":"9","author":"Christein JD","year":"2005","unstructured":"Christein JD, Kendrick ML, Iqbal CW, Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922\u2013927."},{"key":"B106","series-title":"Surgery","first-page":"45","article-title":"A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it's time to randomize","volume":"157","author":"Mehrabi A","year":"2015","unstructured":"Mehrabi A, Hafezi M, Arvin J, A systematic review and meta-analysis of laparoscopic versus open distal pancreatectomy for benign and malignant lesions of the pancreas: it's time to randomize. Surgery 2015;157:45\u201355."},{"key":"B107","series-title":"HPB (Oxford)","first-page":"149","article-title":"Comparison of open with laparoscopic distal pancreatectomy: a single institution\u2019s transition over a 7-year period","volume":"15","author":"Stauffer JA","year":"2013","unstructured":"Stauffer JA, Rosales-Velderrain A, Goldberg RF, Comparison of open with laparoscopic distal pancreatectomy: a single institution\u2019s transition over a 7-year period. HPB (Oxford) 2013;15:149\u2013155."},{"key":"B108","series-title":"JAMA Surg","first-page":"237","article-title":"Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis","volume":"149","author":"Tran Cao HS","year":"2014","unstructured":"Tran Cao HS, Lopez N, Chang DC, Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis. JAMA Surg 2014;149:237\u2013243."},{"key":"B109","series-title":"JAMA Surg","first-page":"1299","article-title":"Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial","volume":"160","author":"Bruna CL","year":"2025","unstructured":"Bruna CL, van Hilst J, Korrel M, Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. JAMA Surg 2025;160:1299\u20131307."},{"key":"B110","series-title":"J Gastrointest Surg","first-page":"1048","article-title":"Resection of tumors of the neck of the pancreas with venous invasion: the \u201cWhipple at the Splenic Artery (WATSA)\u201d procedure","volume":"16","author":"Strasberg SM","year":"2012","unstructured":"Strasberg SM, Sanchez LA, Hawkins WG, Resection of tumors of the neck of the pancreas with venous invasion: the \u201cWhipple at the Splenic Artery (WATSA)\u201d procedure. J Gastrointest Surg 2012;16:1048\u20131054."},{"key":"B111","series-title":"Surgery","first-page":"426","article-title":"Pancreatic neck cancer has specific and oncologic characteristics regarding portal vein invasion and lymph node metastasis","volume":"159","author":"Hirono S","year":"2016","unstructured":"Hirono S, Kawai M, Okada K, Pancreatic neck cancer has specific and oncologic characteristics regarding portal vein invasion and lymph node metastasis. Surgery 2016;159:426\u2013440."},{"key":"B112","series-title":"Ann Surg","first-page":"418","article-title":"Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results","volume":"199","author":"Fortner JG.","year":"1984","unstructured":"Fortner JG. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results. Ann Surg 1984;199:418\u2013425."},{"key":"B113","series-title":"Ann Surg","first-page":"154","article-title":"Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group","volume":"223","author":"Fuhrman GM","year":"1996","unstructured":"Fuhrman GM, Leach SD, Staley CA, Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 1996;223:154\u2013162."},{"key":"B114","series-title":"Br J Surg","first-page":"611","article-title":"Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head","volume":"85","author":"Leach SD","year":"1998","unstructured":"Leach SD, Lee JE, Charnsangavej C, Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998;85:611\u2013617."},{"key":"B115","series-title":"J Am Coll Surg","first-page":"629","article-title":"A simple technique of portal vein resection and reconstruction during pancreaticoduodenectomy","volume":"189","author":"Clavien PA","year":"1999","unstructured":"Clavien PA, Rudiger HA. A simple technique of portal vein resection and reconstruction during pancreaticoduodenectomy. J Am Coll Surg 1999;189:629\u2013634."},{"key":"B116","series-title":"World J Surg","first-page":"926","article-title":"Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer?","volume":"23","author":"Launois B","year":"1999","unstructured":"Launois B, Stasik C, Bardaxoglou E, Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer? World J Surg 1999;23:926\u2013929."},{"key":"B117","series-title":"Hepatogastroenterology","first-page":"492","article-title":"Surgical treatment of pancreatic tumors invading the spleno-mesenteric-portal vessels. An Italian Multicenter Survey","volume":"46","author":"Taschieri AM","year":"1999","unstructured":"Taschieri AM, Elli M, Rovati M, Surgical treatment of pancreatic tumors invading the spleno-mesenteric-portal vessels. An Italian Multicenter Survey. Hepatogastroenterology 1999;46:492\u2013497."},{"key":"B118","series-title":"Surgery","first-page":"158","article-title":"Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy","volume":"129","author":"van Geenen RC","year":"2001","unstructured":"van Geenen RC, ten Kate FJ, de Wit LT, Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001;129:158\u2013163."},{"key":"B119","series-title":"Eur J Surg Oncol","first-page":"371","article-title":"Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis","volume":"40","author":"Yu XZ","year":"2014","unstructured":"Yu XZ, Li J, Fu DL, Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: a meta-analysis. Eur J Surg Oncol 2014;40:371\u2013378."},{"key":"B120","series-title":"J Gastrointest Surg","first-page":"1209","article-title":"Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of \u201cborderline resectable disease\u201d?","volume":"17","author":"Kelly KJ","year":"2013","unstructured":"Kelly KJ, Winslow E, Kooby D, Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of \u201cborderline resectable disease\u201d? J Gastrointest Surg 2013;17:1209\u20131217; discussion 1217."},{"key":"B121","series-title":"Pancreatology","first-page":"154","article-title":"Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer","volume":"26","author":"Franklin O","year":"2026","unstructured":"Franklin O, Stoop TF, Rodriguez Franco S, Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Pancreatology 2026;26:154\u2013163."},{"key":"B122","series-title":"Surgery","first-page":"1039","article-title":"Commentary on: Divestment or skeletonization of the SMA or the hepatic artery for locally advanced pancreatic ductal cancer after neoadjuvant therapy","volume":"169","author":"Del Chiaro M","year":"2021","unstructured":"Del Chiaro M, Schulick RD. Commentary on: Divestment or skeletonization of the SMA or the hepatic artery for locally advanced pancreatic ductal cancer after neoadjuvant therapy. Surgery 2021;169:1039\u20131040."},{"key":"B123","series-title":"Langenbecks Arch Surg","first-page":"1017","article-title":"Pancreatic resection for cancer-the Heidelberg technique","volume":"404","author":"Schneider M","year":"2019","unstructured":"Schneider M, Strobel O, Hackert T, Buchler MW. Pancreatic resection for cancer-the Heidelberg technique. Langenbecks Arch Surg 2019;404:1017\u20131022."},{"key":"B124","series-title":"Surg Gynecol Obstet","first-page":"959","article-title":"Preservation of the pylorus in pancreaticoduodenectomy","volume":"146","author":"Traverso LW","year":"1978","unstructured":"Traverso LW, Longmire WP, Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet 1978;146:959\u2013962."},{"key":"B125","series-title":"Cochrane Database Syst Rev","first-page":"CD006053","article-title":"Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma","volume":"2","author":"Huttner FJ","year":"2016","unstructured":"Huttner FJ, Fitzmaurice C, Schwarzer G, Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev 2016;2:CD006053."},{"key":"B126","series-title":"Ann Surg","first-page":"580","article-title":"A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy","volume":"222","author":"Yeo CJ","year":"1995","unstructured":"Yeo CJ, Cameron JL, Maher MM, A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580\u2013588; discussion 588\u2013592."},{"key":"B127","series-title":"Lancet Oncol","first-page":"655","article-title":"Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial","volume":"14","author":"Topal B","year":"2013","unstructured":"Topal B, Fieuws S, Aerts R, Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol 2013;14:655\u2013662."},{"key":"B128","series-title":"HPB (Oxford)","first-page":"113","article-title":"The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials","volume":"17","author":"Hallet J","year":"2015","unstructured":"Hallet J, Zih FS, Deobald RG, The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials. HPB (Oxford) 2015;17:113\u2013122."},{"key":"B129","series-title":"World J Gastrointest Oncol","first-page":"369","article-title":"Reconstruction after pancreatoduodenectomy: Pancreatojejunostomy vs pancreatogastrostomy","volume":"6","author":"Gomez T","year":"2014","unstructured":"Gomez T, Palomares A, Serradilla M, Tejedor L. Reconstruction after pancreatoduodenectomy: Pancreatojejunostomy vs pancreatogastrostomy. World J Gastrointest Oncol 2014;6:369\u2013376."},{"key":"B130","series-title":"Surgery","first-page":"766","article-title":"Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial","volume":"134","author":"Bassi C","year":"2003","unstructured":"Bassi C, Falconi M, Molinari E, Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery 2003;134:766\u2013771."},{"key":"B131","series-title":"Br J Surg","first-page":"1590","article-title":"Management of the pancreatic stump following pancreaticoduodenectomy","volume":"82","author":"Sikora SS","year":"1995","unstructured":"Sikora SS, Posner MC. Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg 1995;82:1590\u20131597."},{"key":"B132","series-title":"J Am Coll Surg","first-page":"746","article-title":"Prospective trial of a blood supply-based technique of pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure","volume":"194","author":"Strasberg SM","year":"2002","unstructured":"Strasberg SM, Drebin JA, Mokadam NA, Prospective trial of a blood supply-based technique of pancreaticojejunostomy: effect on anastomotic failure in the Whipple procedure. J Am Coll Surg 2002;194:746\u2013758; discussion 759\u2013760."},{"key":"B133","series-title":"J Gastrointest Surg","first-page":"1280","article-title":"Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial","volume":"10","author":"Winter JM","year":"2006","unstructured":"Winter JM, Cameron JL, Campbell KA, Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2006;10:1280\u20131290."},{"key":"B134","series-title":"Ann Surg","first-page":"632","article-title":"Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease","volume":"226","author":"Lowy AM","year":"1997","unstructured":"Lowy AM, Lee JE, Pisters PW, Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg 1997;226:632\u2013641."},{"key":"B135","series-title":"Ann Surg","first-page":"419","article-title":"Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial","volume":"232","author":"Yeo CJ","year":"2000","unstructured":"Yeo CJ, Cameron JL, Lillemoe KD, Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000;232:419\u2013429."},{"key":"B136","series-title":"J Gastrointest Surg","first-page":"766","article-title":"Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial","volume":"8","author":"Lillemoe KD","year":"2004","unstructured":"Lillemoe KD, Cameron JL, Kim MP, Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg 2004;8:766\u2013772."},{"key":"B137","series-title":"N Engl J Med","first-page":"2014","article-title":"Pasireotide for postoperative pancreatic fistula","volume":"370","author":"Allen PJ","year":"2014","unstructured":"Allen PJ, Gonen M, Brennan MF, Pasireotide for postoperative pancreatic fistula. N Engl J Med 2014;370:2014\u20132022."},{"key":"B138","series-title":"Cancer","first-page":"880","article-title":"Lymph node involvement in carcinoma of the head of the pancreas area","volume":"41","author":"Cubilla AL","year":"1978","unstructured":"Cubilla AL, Fortner J, Fitzgerald PJ. Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 1978;41:880\u2013887."},{"key":"B139","series-title":"Ann Surg","first-page":"65","article-title":"Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material","volume":"204","author":"Nagai H","year":"1986","unstructured":"Nagai H, Kuroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986;204:65\u201371."},{"key":"B140","series-title":"World J Surg Oncol","first-page":"123","article-title":"Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery?","volume":"6","author":"Glanemann M","year":"2008","unstructured":"Glanemann M, Shi B, Liang F, Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol 2008;6:123."},{"key":"B141","series-title":"Pancreatic Cancer","first-page":"139","article-title":"Regional lymph node dissection for pancreatic adenocarcinoma","author":"Pisters P","year":"2002","unstructured":"Pisters P, Brennan M. Regional lymph node dissection for pancreatic adenocarcinoma. In: Evans D, Pisters P, Abbruzzese J, eds., eds. Pancreatic Cancer. New York: Springer-Verlag; 2002:139\u2013151."},{"key":"B142","series-title":"Ann Surg","first-page":"508","article-title":"Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group","volume":"228","author":"Pedrazzoli S","year":"1998","unstructured":"Pedrazzoli S, DiCarlo V, Dionigi R, Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508\u2013517."},{"key":"B143","series-title":"Ann Surg","first-page":"613","article-title":"Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome","volume":"229","author":"Yeo CJ","year":"1999","unstructured":"Yeo CJ, Cameron JL, Sohn TA, Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613\u2013622; discussion 622\u2013614."},{"key":"B144","series-title":"J Gastrointest Surg","first-page":"1191","article-title":"Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma\u2013part 3: update on 5-year survival","volume":"9","author":"Riall TS","year":"2005","unstructured":"Riall TS, Cameron JL, Lillemoe KD, Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma\u2013part 3: update on 5-year survival. J Gastrointest Surg 2005;9:1191\u20131204; discussion 1204\u20131196."},{"key":"B145","series-title":"Ann Surg","first-page":"355","article-title":"Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality","volume":"236","author":"Yeo CJ","year":"2002","unstructured":"Yeo CJ, Cameron JL, Lillemoe KD, Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355\u2013366; discussion 366\u2013358."},{"key":"B146","series-title":"J Hepatobiliary Pancreat Sci","first-page":"230","article-title":"Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial","volume":"19","author":"Nimura Y","year":"2012","unstructured":"Nimura Y, Nagino M, Takao S, Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012;19:230\u2013241."},{"key":"B147","series-title":"Br J Surg","first-page":"265","article-title":"Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer","volume":"94","author":"Michalski CW","year":"2007","unstructured":"Michalski CW, Kleeff J, Wente MN, Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265\u2013273."},{"key":"B148","series-title":"World J Surg","first-page":"2708","article-title":"Meta-analysis of the efficacies of extended and standard pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas","volume":"38","author":"Sun J","year":"2014","unstructured":"Sun J, Yang Y, Wang X, Meta-analysis of the efficacies of extended and standard pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas. World J Surg 2014;38:2708\u20132715."},{"key":"B149","series-title":"Surgery","first-page":"591","article-title":"Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)","volume":"156","author":"Tol JA","year":"2014","unstructured":"Tol JA, Gouma DJ, Bassi C, Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156:591\u2013600."},{"key":"B150","series-title":"J Gastrointest Surg","first-page":"651","article-title":"The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence","volume":"12","author":"Farnell MB","year":"2008","unstructured":"Farnell MB, Aranha GV, Nimura Y, Michelassi F. The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence. J Gastrointest Surg 2008;12:651\u2013656."},{"key":"B151","series-title":"World J Gastrointest Surg","first-page":"39","article-title":"Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence","volume":"2","author":"Shrikhande SV","year":"2010","unstructured":"Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence. World J Gastrointest Surg 2010;2:39\u201346."},{"key":"B152","series-title":"Ann Surg Oncol","first-page":"2330","article-title":"Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma","volume":"14","author":"Cordera F","year":"2007","unstructured":"Cordera F, Arciero CA, Li T, Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol 2007;14:2330\u20132336."},{"key":"B153","series-title":"J Am Coll Surg","first-page":"345","article-title":"The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma","volume":"203","author":"Shimada K","year":"2006","unstructured":"Shimada K, Sakamoto Y, Sano T, Kosuge T. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg 2006;203:345\u2013352."},{"key":"B154","series-title":"Ann Surg","first-page":"638","article-title":"Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy","volume":"222","author":"Lieberman MD","year":"1995","unstructured":"Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638\u2013645."},{"key":"B155","series-title":"Ann Surg","first-page":"509","article-title":"Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy","volume":"237","author":"Ho V","year":"2003","unstructured":"Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 2003;237:509\u2013514."},{"key":"B156","series-title":"Am J Med Qual","first-page":"193","article-title":"The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York State","volume":"11","author":"Imperato PJ","year":"1996","unstructured":"Imperato PJ, Nenner RP, Starr HA, The effects of regionalization on clinical outcomes for a high risk surgical procedure: a study of the Whipple procedure in New York State. Am J Med Qual 1996;11:193\u2013197."},{"key":"B157","series-title":"J Gastrointest Surg","first-page":"21","article-title":"Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality","volume":"5","author":"Rosemurgy AS","year":"2001","unstructured":"Rosemurgy AS, Bloomston M, Serafini FM, Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg 2001;5:21\u201326."},{"key":"B158","series-title":"Ann Surg","first-page":"429","article-title":"Importance of hospital volume in the overall management of pancreatic cancer","volume":"228","author":"Sosa JA","year":"1998","unstructured":"Sosa JA, Bowman HM, Gordon TA, Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429\u2013438."},{"key":"B159","series-title":"Ann Surg","first-page":"786","article-title":"Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume","volume":"232","author":"Gouma DJ","year":"2000","unstructured":"Gouma DJ, van Geenen RC, van Gulik TM, Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786\u2013795."},{"key":"B160","series-title":"Surgery","first-page":"250","article-title":"Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy","volume":"125","author":"Birkmeyer JD","year":"1999","unstructured":"Birkmeyer JD, Finlayson SR, Tosteson AN, Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 1999;125:250\u2013256."},{"key":"B161","series-title":"N Engl J Med","first-page":"1128","article-title":"Hospital volume and surgical mortality in the United States","volume":"346","author":"Birkmeyer JD","year":"2002","unstructured":"Birkmeyer JD, Siewers AE, Finlayson EV, Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128\u20131137."},{"key":"B162","series-title":"Cancer","first-page":"1227","article-title":"Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume","volume":"110","author":"Bilimoria KY","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer 2007;110:1227\u20131234."},{"key":"B163","series-title":"Am Surg","first-page":"225","article-title":"Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma","volume":"78","author":"La Torre M","year":"2012","unstructured":"La Torre M, Nigri G, Ferrari L, Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2012;78:225\u2013229."},{"key":"B164","series-title":"JAMA","first-page":"1473","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle H","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473\u20131481."},{"key":"B165","series-title":"J Clin Oncol","first-page":"3330","article-title":"CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial","volume":"35","author":"Sinn M","year":"2017","unstructured":"Sinn M, Bahra M, Liersch T, CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial. J Clin Oncol 2017;35:3330\u20133337."},{"key":"B166","series-title":"Ann Oncol","first-page":"S1334","article-title":"LBA57 Unicancer PRODIGE 24\/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)","volume":"32","author":"Conroy T","year":"2021","unstructured":"Conroy T, Hammel P, Turpin A, LBA57 Unicancer PRODIGE 24\/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC). Ann Oncol 2021;32:S1334."},{"key":"B167","series-title":"J Clin Oncol","first-page":"504","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle JW","year":"2014","unstructured":"Valle JW, Palmer D, Jackson R, Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 2014;32:504\u2013512."},{"key":"B168","series-title":"Ann Surg Oncol","first-page":"1319","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine WF","year":"2011","unstructured":"Regine WF, Winter KA, Abrams R, Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial. Ann Surg Oncol 2011;18:1319\u20131326."},{"key":"B169","series-title":"J Clin Oncol","first-page":"4005","article-title":"NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)","volume":"42","author":"Abrams RA","year":"2024","unstructured":"Abrams RA, Winter KA, Goodman KA, NRG Oncology\/RTOG 0848: Results after adjuvant chemotherapy +\/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA). J Clin Oncol 2024;42:4005\u20134005."},{"key":"B170","series-title":"J Clin Oncol","first-page":"JCO2502520","article-title":"Adjuvant chemotherapy +\/- chemoradiotherapy for adenocarcinoma of the pancreatic head: Results of the radiotherapy random assignment of NRG Oncology\/RTOG 0848","author":"Abrams RA","year":"2026","unstructured":"Abrams RA, Winter KA, Goodman KA, Adjuvant chemotherapy +\/- chemoradiotherapy for adenocarcinoma of the pancreatic head: Results of the radiotherapy random assignment of NRG Oncology\/RTOG 0848. J Clin Oncol 2026:JCO2502520."},{"key":"B171","series-title":"HPB (Oxford)","first-page":"365","article-title":"Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy","volume":"14","author":"Tzeng CW","year":"2012","unstructured":"Tzeng CW, Fleming JB, Lee JE, Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012;14:365\u2013372."},{"key":"B172","series-title":"Ann Surg Oncol","first-page":"2197","article-title":"Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis","volume":"20","author":"Tzeng CW","year":"2013","unstructured":"Tzeng CW, Abbott DE, Cantor SB, Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 2013;20:2197\u20132203."},{"key":"B173","series-title":"J Gastrointest Surg","first-page":"121","article-title":"Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study","volume":"16","author":"Witkowski ER","year":"2012","unstructured":"Witkowski ER, Smith JK, Ragulin-Coyne E, Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg 2012;16:121\u2013128."},{"key":"B174","series-title":"Pancreatology","first-page":"1124","article-title":"Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis","volume":"16","author":"Zhou Y","year":"2016","unstructured":"Zhou Y, Song A, Wu L, Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: A pooled analysis. Pancreatology 2016;16:1124\u20131128."},{"key":"B175","series-title":"Ann Surg Oncol","first-page":"836","article-title":"Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma","volume":"16","author":"Katz MH","year":"2009","unstructured":"Katz MH, Wang H, Fleming JB, Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:836\u2013847."},{"key":"B176","series-title":"J Gastrointest Surg","first-page":"1611","article-title":"Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival","volume":"15","author":"Arnaoutakis GJ","year":"2011","unstructured":"Arnaoutakis GJ, Rangachari D, Laheru DA, Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg 2011;15:1611\u20131617."},{"key":"B177","series-title":"Surgery","first-page":"654","article-title":"Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer","volume":"174","author":"Stuart CM","year":"2023","unstructured":"Stuart CM, Kirsch MJ, Zhuang Y, Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Surgery 2023;174:654\u2013659."},{"key":"B178","series-title":"HPB (Oxford)","first-page":"998","article-title":"Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival","volume":"21","author":"Groot VP","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB (Oxford) 2019;21:998\u20131008."},{"key":"B179","series-title":"Surg Case Rep","first-page":"66","article-title":"Long-term survival after repeated resection for lung metastasis originating from pancreatic cancer: a case report","volume":"6","author":"Uesato Y","year":"2020","unstructured":"Uesato Y, Tamashiro K, Takatsuki M. Long-term survival after repeated resection for lung metastasis originating from pancreatic cancer: a case report. Surg Case Rep 2020;6:66."},{"key":"B180","series-title":"Updates Surg","article-title":"Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer","author":"Nachira D","year":"2026","unstructured":"Nachira D, Calabrese G, Bertolaccini L, Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer. Updates Surg 2026."},{"key":"B181","series-title":"Surg Oncol","first-page":"16","article-title":"Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection","volume":"31","author":"Ilmer M","year":"2019","unstructured":"Ilmer M, Schiergens TS, Renz BW, Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Surg Oncol 2019;31:16\u201321."},{"key":"B182","series-title":"Hepatogastroenterology","first-page":"246","article-title":"Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas","volume":"52","author":"Zimmermann FB","year":"2005","unstructured":"Zimmermann FB, Jeremic B, Lersch C, Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas. Hepatogastroenterology 2005;52:246\u2013250."},{"key":"B183","series-title":"J Clin Oncol","first-page":"3270","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin JD","year":"2002","unstructured":"Berlin JD, Catalano P, Thomas JP, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270\u20133275."},{"key":"B184","series-title":"J Clin Oncol","first-page":"1645","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci G","year":"2010","unstructured":"Colucci G, Labianca R, Di Costanzo F, Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645\u20131651."},{"key":"B185","series-title":"Br J Cancer","first-page":"481","article-title":"Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study","volume":"94","author":"Demols A","year":"2006","unstructured":"Demols A, Peeters M, Polus M, Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481\u2013485."},{"key":"B186","series-title":"Cancer Chemother Pharmacol","first-page":"167","article-title":"The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis","volume":"61","author":"Fine RL","year":"2008","unstructured":"Fine RL, Fogelman DR, Schreibman SM, The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167\u2013175."},{"key":"B187","series-title":"J Clin Oncol","first-page":"3946","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann V","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F, Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946\u20133952."},{"key":"B188","series-title":"J Clin Oncol","first-page":"2212","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann R","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212\u20132217."},{"key":"B189","series-title":"J Clin Oncol","first-page":"3509","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet C","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P, Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509\u20133516."},{"key":"B190","series-title":"J Clin Oncol","first-page":"3778","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin E","year":"2009","unstructured":"Poplin E, Feng Y, Berlin J, Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778\u20133785."},{"key":"B191","series-title":"Lancet Oncol","first-page":"369","article-title":"Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial","volume":"6","author":"Reni M","year":"2005","unstructured":"Reni M, Cordio S, Milandri C, Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369\u2013376."},{"key":"B192","series-title":"J Clin Oncol","first-page":"3776","article-title":"Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate","volume":"22","author":"Rocha Lima CM","year":"2004","unstructured":"Rocha Lima CM, Green MR, Rotche R, Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776\u20133783."},{"key":"B193","series-title":"Eur J Cancer","first-page":"593","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials","volume":"49","author":"Ciliberto D","year":"2013","unstructured":"Ciliberto D, Botta C, Correale P, Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013;49:593\u2013603."},{"key":"B194","series-title":"World J Gastroenterol","first-page":"4944","article-title":"Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?","volume":"18","author":"Sun C","year":"2012","unstructured":"Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012;18:4944\u20134958."},{"key":"B195","series-title":"J Clin Oncol","first-page":"4548","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff DD","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 2011;29:4548\u20134554."},{"key":"B196","series-title":"Lancet Gastroenterol Hepatol","first-page":"285","article-title":"Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study","volume":"5","author":"Philip PA","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020;5:285\u2013294."},{"key":"B197","series-title":"N Engl J Med","first-page":"1691","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff DD","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691\u20131703."},{"key":"B198","series-title":"Ann Oncol","first-page":"654","article-title":"CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"27","author":"Chiorean EG","year":"2016","unstructured":"Chiorean EG, Von Hoff DD, Reni M, CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016;27:654\u2013660."},{"key":"B199","series-title":"Eur J Cancer","first-page":"85","article-title":"Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)","volume":"52","author":"Goldstein D","year":"2016","unstructured":"Goldstein D, Von Hoff DD, Moore M, Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer 2016;52:85\u201391."},{"key":"B200","series-title":"J Natl Cancer Inst","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein D","year":"2015","unstructured":"Goldstein D, El-Maraghi RH, Hammel P, nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107."},{"key":"B201","series-title":"Oncologist","first-page":"143","article-title":"Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"20","author":"Tabernero J","year":"2015","unstructured":"Tabernero J, Chiorean EG, Infante JR, Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015;20:143\u2013150."},{"key":"B202","series-title":"Eur J Cancer","first-page":"1135","article-title":"Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution","volume":"32A","author":"Buccheri G","year":"1996","unstructured":"Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A:1135\u20131141."},{"key":"B203","series-title":"Br J Cancer","first-page":"1132","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan T","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132\u20131138."},{"key":"B204","series-title":"Cancer","first-page":"1004","article-title":"Prognostic impact of BRCA1 pathogenic and BRCA1\/BRCA2 unclassified variant mutations in patients with ovarian carcinoma","volume":"104","author":"Majdak EJ","year":"2005","unstructured":"Majdak EJ, Debniak J, Milczek T, Prognostic impact of BRCA1 pathogenic and BRCA1\/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:1004\u20131012."},{"key":"B205","series-title":"Breast Cancer Res","first-page":"R47","article-title":"Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes","volume":"11","author":"Stefansson OA","year":"2009","unstructured":"Stefansson OA, Jonasson JG, Johannsson OT, Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47."},{"key":"B206","series-title":"Cancer Chemother Pharmacol","first-page":"489","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman D","year":"2015","unstructured":"Fogelman D, Sugar EA, Oliver G, Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2015;76:489\u2013498."},{"key":"B207","series-title":"J Clin Oncol","first-page":"1378","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly EM","year":"2020","unstructured":"O\u2019Reilly EM, Lee JW, Zalupski M, Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation. J Clin Oncol 2020;38:1378\u20131388."},{"key":"B208","series-title":"J Clin Oncol","first-page":"5513","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham D","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513\u20135518."},{"key":"B209","series-title":"Medicine (Baltimore)","first-page":"e5702","article-title":"A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea","volume":"96","author":"Lee HS","year":"2017","unstructured":"Lee HS, Chung MJ, Park JY, A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore) 2017;96:e5702."},{"key":"B210","series-title":"PLoS One","first-page":"e104346","article-title":"Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Li Q","year":"2014","unstructured":"Li Q, Yan H, Liu W, Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346."},{"key":"B211","series-title":"Am J Clin Oncol","first-page":"411","article-title":"Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas","volume":"35","author":"Ko AH","year":"2012","unstructured":"Ko AH, Espinoza AM, Jones KA, Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol 2012;35:411\u2013417."},{"key":"B212","series-title":"JAMA Oncol","first-page":"125","article-title":"Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b\/2 pilot clinical trial","volume":"6","author":"Jameson GS","year":"2020","unstructured":"Jameson GS, Borazanci E, Babiker HM, Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: A phase 1b\/2 pilot clinical trial. JAMA Oncol 2020;6:125\u2013132."},{"key":"B213","series-title":"JAMA Oncol","first-page":"824","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial","volume":"5","author":"Shroff RT","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial. JAMA Oncol 2019;5:824\u2013830."},{"key":"B214","series-title":"J Clin Oncol","first-page":"1228","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer\u2013a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy T","year":"2005","unstructured":"Conroy T, Paillot B, Francois E, Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer\u2013a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228\u20131236."},{"key":"B215","series-title":"J Clin Oncol","first-page":"4516","article-title":"Randomized phase II trial comparing folfirinox (5FU\/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]","volume":"25","author":"Ychou M","year":"2007","unstructured":"Ychou M, Desseigne F, Guimbaud R, Randomized phase II trial comparing folfirinox (5FU\/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]. J Clin Oncol 2007;25 (June 20 Suppl):4516."},{"key":"B216","series-title":"N Engl J Med","first-page":"1817","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy T","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817\u20131825."},{"key":"B217","series-title":"J Clin Oncol","first-page":"23","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade S","year":"2013","unstructured":"Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ ACCORD 11 randomized trial. J Clin Oncol 2013;31:23\u201329."},{"key":"B218","series-title":"Lancet Oncol","first-page":"801","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker M","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016;17:801\u2013810."},{"key":"B219","series-title":"Ann Surg Oncol","first-page":"3512","article-title":"FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma","volume":"22","author":"Sadot E","year":"2015","unstructured":"Sadot E, Doussot A, O\u2019Reilly EM, FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol 2015;22:3512\u20133521."},{"key":"B220","series-title":"J Clin Oncol","first-page":"2255","article-title":"PRODIGE 29-UCGI 26 (NEOPAN): A phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma","volume":"43","author":"Ducreux M","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y, PRODIGE 29-UCGI 26 (NEOPAN): A phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol 2025;43:2255\u20132264."},{"key":"B221","series-title":"ASCO Meeting Abstracts","first-page":"4057","article-title":"Activity of front-line FOLFIRINOX (FFX) in stage III\/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]","volume":"30","author":"Lowery MA","year":"2012","unstructured":"Lowery MA, Yu KH, Adel NG, Activity of front-line FOLFIRINOX (FFX) in stage III\/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. ASCO Meeting Abstracts 2012;30:4057."},{"key":"B222","series-title":"Br J Cancer","first-page":"737","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"Stein SM","year":"2016","unstructured":"Stein SM, James ES, Deng Y, Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016;114:737\u2013743."},{"key":"B223","series-title":"Oncologist","first-page":"543","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience","volume":"18","author":"Faris JE","year":"2013","unstructured":"Faris JE, Blaszkowsky LS, McDermott S, FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013;18:543\u2013548."},{"key":"B224","series-title":"Eur J Cancer","first-page":"14","article-title":"First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I\/II study","volume":"151","author":"Wainberg ZA","year":"2021","unstructured":"Wainberg ZA, Bekaii-Saab T, Boland PM, First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I\/II study. Eur J Cancer 2021;151:14\u201324."},{"key":"B225","series-title":"J Clin Oncol","first-page":"LBA661","article-title":"NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg ZA","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol 2023;41:LBA661\u2013LBA661."},{"key":"B226","series-title":"Lancet","first-page":"545","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam A","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545\u2013557."},{"key":"B227","series-title":"J Clin Oncol","first-page":"3914","article-title":"PANCREOX: A randomized phase iii study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill S","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, PANCREOX: A randomized phase iii study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol 2016;34:3914\u20133920."},{"key":"B228","series-title":"J Clin Oncol","first-page":"1370","article-title":"Second-line combination therapies in pancreatic cancer: Where are we now?","volume":"35","author":"Uccello M","year":"2017","unstructured":"Uccello M, Moschetta M, Arkenau HT. Second-line combination therapies in pancreatic cancer: Where are we now? J Clin Oncol 2017;35:1370\u20131371."},{"key":"B229","series-title":"JAMA Oncol","first-page":"516","article-title":"Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial","volume":"3","author":"Chung V","year":"2017","unstructured":"Chung V, McDonough S, Philip PA, Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol 2017;3:516\u2013522."},{"key":"B230","series-title":"Anticancer Drugs","first-page":"980","article-title":"FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience","volume":"24","author":"Moretto R","year":"2013","unstructured":"Moretto R, Raimondo L, De Stefano A, FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. Anticancer Drugs 2013;24:980\u2013985."},{"key":"B231","series-title":"World J Gastroenterol","first-page":"4533","article-title":"FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts","volume":"18","author":"Neuzillet C","year":"2012","unstructured":"Neuzillet C, Hentic O, Rousseau B, FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012;18:4533\u20134541."},{"key":"B232","series-title":"Br J Cancer","first-page":"1658","article-title":"A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"101","author":"Yoo C","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009;101:1658\u20131663."},{"key":"B233","series-title":"Cancer Chemother Pharmacol","first-page":"1641","article-title":"FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study","volume":"69","author":"Zaniboni A","year":"2012","unstructured":"Zaniboni A, Aitini E, Barni S, FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012;69:1641\u20131645."},{"key":"B234","series-title":"Gut","first-page":"751","article-title":"Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019 (AIO-PK0104)","volume":"62","author":"Heinemann V","year":"2013","unstructured":"Heinemann V, Vehling-Kaiser U, Waldschmidt D, Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019 (AIO-PK0104). Gut 2013;62:751\u2013759."},{"key":"B235","series-title":"J Clin Oncol","first-page":"160","article-title":"Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer","volume":"20","author":"Cartwright TH","year":"2002","unstructured":"Cartwright TH, Cohn A, Varkey JA, Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160\u2013164."},{"key":"B236","series-title":"Cancer","first-page":"2046","article-title":"Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer","volume":"113","author":"Xiong HQ","year":"2008","unstructured":"Xiong HQ, Varadhachary GR, Blais JC, Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:2046\u20132052."},{"key":"B237","series-title":"Eur J Cancer","first-page":"1676","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer U","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676\u20131681."},{"key":"B238","series-title":"J Clin Oncol","first-page":"2423","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle H","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:2423\u20132429."},{"key":"B239","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018;378:731\u2013739."},{"key":"B240","series-title":"Lancet Oncol","first-page":"531","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020;21:531\u2013540."},{"key":"B241","series-title":"Lancet Oncol","first-page":"271","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 2020;21:271\u2013282."},{"key":"B242","series-title":"Clin Cancer Res","first-page":"1302","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri GD","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 2022;28:1302\u20131312."},{"key":"B243","series-title":"Ann Oncol","first-page":"S787","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon BJ","year":"2023","unstructured":"Solomon BJ, Drilon A, Lin JJ, 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I\/II TRIDENT-1 trial. Ann Oncol 2023;34:S787\u2013S788."},{"key":"B244","series-title":"N Engl J Med","first-page":"1207","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong DS","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med 2020;383:1207\u20131217."},{"key":"B245","series-title":"N Engl J Med","first-page":"33","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler JH","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388:33\u201343."},{"key":"B246","series-title":"J Clin Oncol","first-page":"519","article-title":"KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation","volume":"40","author":"Bekaii-Saab TS","year":"2022","unstructured":"Bekaii-Saab TS, Spira AI, Yaeger R, KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol 2022;40:519\u2013519."},{"key":"B247","series-title":"Cold Spring Harb Perspect Med","article-title":"KRAS: The critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters AM","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med 2018;8."},{"key":"B248","series-title":"Lancet Oncol","first-page":"925","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant S","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 2023;24:925\u2013935."},{"key":"B249","series-title":"NPJ Precis Oncol","first-page":"207","article-title":"FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer","volume":"8","author":"Stein L","year":"2024","unstructured":"Stein L, Murugesan K, Reeser JW, FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer. NPJ Precis Oncol 2024;8:207."},{"key":"B250","series-title":"Lancet Oncol","first-page":"1234","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open- label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah V","year":"2020","unstructured":"Subbiah V, Lassen U, Elez E, Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open- label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234\u20131243."},{"key":"B251","series-title":"J Clin Oncol","first-page":"3895","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: Results of the NCI-MATCH trial Subprotocol H","volume":"38","author":"Salama AKS","year":"2020","unstructured":"Salama AKS, Li S, Macrae ER, Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: Results of the NCI-MATCH trial Subprotocol H. J Clin Oncol 2020;38:3895\u20133904."},{"key":"B252","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."},{"key":"B253","series-title":"J Clin Oncol","first-page":"47","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary RESULTS FROm the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam F","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary RESULTS FROm the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42:47\u201358."},{"key":"B254","series-title":"J Natl Cancer Inst","article-title":"NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer","author":"Schram AM","year":"2025","unstructured":"Schram AM, Yang SR, Kahn G, NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. J Natl Cancer Inst 2025."},{"key":"B255","series-title":"N Engl J Med","first-page":"2509","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"Le DT, Uram JN, Wang H, PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509\u20132520."},{"key":"B256","series-title":"Science","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409\u2013413."},{"key":"B257","series-title":"J Clin Oncol","first-page":"1","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1\u201310."},{"key":"B258","series-title":"Ann Oncol","first-page":"929","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio M","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33:929\u2013938."},{"key":"B259","series-title":"Eur J Cancer","first-page":"185","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le DT","year":"2023","unstructured":"Le DT, Diaz LA, Jr., Kim TW, Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer 2023;186:185\u2013195."},{"key":"B260","series-title":"Lancet Oncol","first-page":"121","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Geoerger B","year":"2020","unstructured":"Geoerger B, Kang HJ, Yalon-Oren M, Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1\u20132 trial. Lancet Oncol 2020;21:121\u2013133."},{"key":"B261","series-title":"JAMA Netw Open","first-page":"e2341165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial","volume":"6","author":"Andre T","year":"2023","unstructured":"Andre T, Berton D, Curigliano G, Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: A nonrandomized controlled trial. JAMA Netw Open 2023;6:e2341165."},{"key":"B262","series-title":"Cancer Research","first-page":"CT022","article-title":"Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"82","author":"Schenker M","year":"2022","unstructured":"Schenker M, Burotto M, Richardet M, Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Cancer Research 2022;82:CT022\u2013CT022."},{"key":"B263","series-title":"J Clin Oncol","first-page":"3795","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): A multicenter, randomized phase II trial","volume":"42","author":"Ludmir EB","year":"2024","unstructured":"Ludmir EB, Sherry AD, Fellman BM, Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): A multicenter, randomized phase II trial. J Clin Oncol 2024;42:3795\u20133805."},{"key":"B264","series-title":"J Clin Oncol","first-page":"244","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman B","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 2015;33:244\u2013250."},{"key":"B265","series-title":"N Engl J Med","first-page":"317","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317\u2013327."},{"key":"B266","series-title":"J Clin Oncol","first-page":"2497","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss KA","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 2021;39:2497\u20132505."},{"key":"B267","series-title":"N Engl J Med","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","author":"O\u2019Reilly EM","year":"2026","unstructured":"O\u2019Reilly EM, Wainberg ZA, Hendifar AE, Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med 2026."},{"key":"B268","series-title":"Journal of Clinical Oncology","first-page":"LBA5","article-title":"Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study","volume":"44","author":"Wolpin BM","year":"2026","unstructured":"Wolpin BM, Wainberg ZA, Hendifar A, Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study. Journal of Clinical Oncology 2026;44:LBA5\u2013LBA5."},{"key":"B269","series-title":"J Gastrointest Oncol","first-page":"436","article-title":"Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new","volume":"6","author":"Boyle J","year":"2015","unstructured":"Boyle J, Czito B, Willett C, Palta M. Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. J Gastrointest Oncol 2015;6:436\u2013444."},{"key":"B270","series-title":"Int J Radiat Oncol Biol Phys","first-page":"516","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong MD","year":"2013","unstructured":"Chuong MD, Springett GM, Freilich JM, Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013;86:516\u2013522."},{"key":"B271","series-title":"Am J Clin Oncol","first-page":"63","article-title":"Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas","volume":"34","author":"Rwigema JC","year":"2011","unstructured":"Rwigema JC, Parikh SD, Heron DE, Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2011;34:63\u201369."},{"key":"B272","series-title":"Radiat Oncol","first-page":"148","article-title":"SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience","volume":"8","author":"Tozzi A","year":"2013","unstructured":"Tozzi A, Comito T, Alongi F, SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiat Oncol 2013;8:148."},{"key":"B273","series-title":"J Gastrointest Oncol","first-page":"343","article-title":"Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions","volume":"4","author":"Wild AT","year":"2013","unstructured":"Wild AT, Hiniker SM, Chang DT, Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol 2013;4:343\u2013351."},{"key":"B274","series-title":"Cancer","first-page":"3486","article-title":"Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation","volume":"123","author":"Zhong J","year":"2017","unstructured":"Zhong J, Patel K, Switchenko J, Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer 2017;123:3486\u20133493."},{"key":"B275","series-title":"Pract Radiat Oncol","first-page":"417","article-title":"Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer","volume":"6","author":"Rao AD","year":"2016","unstructured":"Rao AD, Sugar EA, Chang DT, Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Pract Radiat Oncol 2016;6:417\u2013424."},{"key":"B276","series-title":"Int J Radiat Oncol Biol Phys","first-page":"571","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild AT","year":"2016","unstructured":"Wild AT, Herman JM, Dholakia AS, Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2016;94:571\u2013579."},{"key":"B277","series-title":"N Engl J Med","first-page":"2713","article-title":"Chemotherapy for pancreatic cancer","volume":"350","author":"Crane CH","year":"2004","unstructured":"Crane CH, Ben-Josef E, Small W, Jr. Chemotherapy for pancreatic cancer. N Engl J Med 2004;350:2713\u20132715; author reply 2713\u20132715."},{"key":"B278","series-title":"Int J Radiat Oncol Biol Phys","first-page":"965","article-title":"A challenge to the therapeutic nihilism of ESPAC-1","volume":"61","author":"Koshy MC","year":"2005","unstructured":"Koshy MC, Landry JC, Cavanaugh SX, A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005;61:965\u2013966."},{"key":"B279","series-title":"N Engl J Med","first-page":"2713","article-title":"Chemotherapy for pancreatic cancer","volume":"350","author":"Morris SL","year":"2004","unstructured":"Morris SL, Beasley M, Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med 2004;350:2713\u20132715; author reply 2713\u20132715."},{"key":"B280","series-title":"J Clin Oncol","first-page":"4450","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem JL","year":"2010","unstructured":"Van Laethem JL, Hammel P, Mornex F, Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study. J Clin Oncol 2010;28:4450\u20134456."},{"key":"B281","series-title":"J Clin Oncol","first-page":"4077","article-title":"Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma","volume":"30","author":"Schmidt J","year":"2012","unstructured":"Schmidt J, Abel U, Debus J, Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012;30:4077\u20134083."},{"key":"B282","series-title":"Arch Surg","first-page":"899","article-title":"Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection","volume":"120","author":"Kalser MH","year":"1985","unstructured":"Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899\u2013903."},{"key":"B283","series-title":"Cancer","first-page":"1705","article-title":"Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group","volume":"48","author":"Moertel CG","year":"1981","unstructured":"Moertel CG, Frytak S, Hahn RG, Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705\u20131710."},{"key":"B284","series-title":"Ann Surg","first-page":"734","article-title":"Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891","volume":"246","author":"Smeenk HG","year":"2007","unstructured":"Smeenk HG, van Eijck CH, Hop WC, Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007;246:734\u2013740."},{"key":"B285","series-title":"Ann Surg Oncol","first-page":"3634","article-title":"Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base","volume":"20","author":"Kooby DA","year":"2013","unstructured":"Kooby DA, Gillespie TW, Liu Y, Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base. Ann Surg Oncol 2013;20:3634\u20133642."},{"key":"B286","series-title":"Int J Radiat Oncol Biol Phys","first-page":"911","article-title":"Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer","volume":"90","author":"Morganti AG","year":"2014","unstructured":"Morganti AG, Falconi M, van Stiphout RG, Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;90:911\u2013917."},{"key":"B287","series-title":"Am J Clin Oncol","first-page":"173","article-title":"Results of the NRG Oncology\/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: A phase II randomized clinical trial","volume":"43","author":"Abrams RA","year":"2020","unstructured":"Abrams RA, Winter KA, Safran H, Results of the NRG Oncology\/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: A phase II randomized clinical trial. Am J Clin Oncol 2020;43:173\u2013179."},{"key":"B288","series-title":"Ann Surg","first-page":"758","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial","volume":"234","author":"Neoptolemos JP","year":"2001","unstructured":"Neoptolemos JP, Stocken DD, Dunn JA, Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758\u2013768."},{"key":"B289","series-title":"J Clin Oncol","first-page":"3503","article-title":"Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital","volume":"26","author":"Herman JM","year":"2008","unstructured":"Herman JM, Swartz MJ, Hsu CC, Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503\u20133510."},{"key":"B290","series-title":"J Clin Oncol","first-page":"3511","article-title":"Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975\u20132005)","volume":"26","author":"Corsini MM","year":"2008","unstructured":"Corsini MM, Miller RC, Haddock MG, Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975\u20132005). J Clin Oncol 2008;26:3511\u20133516."},{"key":"B291","series-title":"Ann Surg Oncol","first-page":"981","article-title":"Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study","volume":"17","author":"Hsu CC","year":"2010","unstructured":"Hsu CC, Herman JM, Corsini MM, Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981\u2013990."},{"key":"B292","series-title":"Arch Surg","first-page":"75","article-title":"Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials","volume":"143","author":"Butturini G","year":"2008","unstructured":"Butturini G, Stocken DD, Wente MN, Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008;143:75\u201383; discussion 83."},{"key":"B293","series-title":"J Natl Cancer Inst","first-page":"751","article-title":"Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group","volume":"80","year":"1988","unstructured":"Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751\u2013755."},{"key":"B294","series-title":"J Clin Oncol","first-page":"373","article-title":"Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2013an Eastern Cooperative Oncology Group study","volume":"3","author":"Klaassen DJ","year":"1985","unstructured":"Klaassen DJ, MacIntyre JM, Catton GE, Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil\u2013an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373\u2013378."},{"key":"B295","series-title":"Int J Gastrointest Cancer","first-page":"107","article-title":"Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas","volume":"34","author":"Blackstock AW","year":"2003","unstructured":"Blackstock AW, Tepper JE, Niedwiecki D, Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003;34:107\u2013116."},{"key":"B296","series-title":"Onkologie","first-page":"436","article-title":"Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study","volume":"23","author":"Brunner TB","year":"2000","unstructured":"Brunner TB, Grabenbauer GG, Kastl S, Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study. Onkologie 2000;23:436\u2013442."},{"key":"B297","series-title":"Am J Clin Oncol","first-page":"161","article-title":"Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703)","volume":"20","author":"Thomas CR, Jr.","year":"1997","unstructured":"Thomas CR, Jr., Weiden PL, Traverso LW, Thompson T. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). Am J Clin Oncol 1997;20:161\u2013165."},{"key":"B298","series-title":"J Natl Compr Canc Netw","first-page":"167","article-title":"Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma","volume":"12","author":"Cinar P","year":"2014","unstructured":"Cinar P, Ko AH. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw 2014;12:167\u2013172."},{"key":"B299","series-title":"J Clin Oncol","first-page":"4105","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer PJ, Sr.","year":"2011","unstructured":"Loehrer PJ, Sr., Feng Y, Cardenes H, Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:4105\u20134112."},{"key":"B300","series-title":"J Clin Oncol","first-page":"4066","article-title":"Locally advanced pancreatic cancer: where should we go from here?","volume":"29","author":"Philip PA.","year":"2011","unstructured":"Philip PA. Locally advanced pancreatic cancer: where should we go from here? J Clin Oncol 2011;29:4066\u20134068."},{"key":"B301","series-title":"Ann Oncol","first-page":"1592","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study","volume":"19","author":"Chauffert B","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study. Ann Oncol 2008;19:1592\u20131599."},{"key":"B302","series-title":"Cancer","first-page":"665","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang DT","year":"2009","unstructured":"Chang DT, Schellenberg D, Shen J, Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009;115:665\u2013672."},{"key":"B303","series-title":"Int J Radiat Oncol Biol Phys","first-page":"735","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan A","year":"2010","unstructured":"Mahadevan A, Jain S, Goldstein M, Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;78:735\u2013742."},{"key":"B304","series-title":"Med Dosim","first-page":"47","article-title":"Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer","volume":"40","author":"Yang W","year":"2015","unstructured":"Yang W, Reznik R, Fraass BA, Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation therapy for pancreatic cancer. Med Dosim 2015;40:47\u201352."},{"key":"B305","series-title":"World J Gastroenterol","first-page":"7461","article-title":"Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis","volume":"19","author":"Chen Y","year":"2013","unstructured":"Chen Y, Sun XJ, Jiang TH, Mao AW. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastroenterol 2013;19:7461\u20137471."},{"key":"B306","series-title":"Int J Radiat Oncol Biol Phys","first-page":"801","article-title":"Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer","volume":"68","author":"Murphy JD","year":"2007","unstructured":"Murphy JD, Adusumilli S, Griffith KA, Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801\u2013808."},{"key":"B307","series-title":"Am J Clin Oncol","first-page":"115","article-title":"Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer","volume":"34","author":"Shibuya K","year":"2010","unstructured":"Shibuya K, Oya N, Fujii T, Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. Am J Clin Oncol 2010;34:115\u2013119."},{"key":"B308","series-title":"Radiother Oncol","first-page":"114","article-title":"Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer","volume":"99","author":"Huang J","year":"2011","unstructured":"Huang J, Robertson JM, Margolis J, Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol 2011;99:114\u2013119."},{"key":"B309","series-title":"Br J Cancer","first-page":"1264","article-title":"Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer","volume":"116","author":"Hurt CN","year":"2017","unstructured":"Hurt CN, Falk S, Crosby T, Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer 2017;116:1264\u20131270."},{"key":"B310","series-title":"Lancet Oncol","first-page":"317","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee S","year":"2013","unstructured":"Mukherjee S, Hurt CN, Bridgewater J, Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013;14:317\u2013326."},{"key":"B311","series-title":"Int J Radiat Oncol Biol Phys","first-page":"810","article-title":"Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer","volume":"93","author":"Hurt CN","year":"2015","unstructured":"Hurt CN, Mukherjee S, Bridgewater J, Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2015;93:810\u2013818."},{"key":"B312","series-title":"JAMA","first-page":"1844","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel P","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA 2016;315:1844\u20131853."},{"key":"B313","series-title":"J Clin Oncol","first-page":"3266","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: The randomized CONKO-007 trial","volume":"43","author":"Fietkau R","year":"2025","unstructured":"Fietkau R, Ghadimi M, Grutzmann R, Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: The randomized CONKO-007 trial. J Clin Oncol 2025;43:3266\u20133278."},{"key":"B314","series-title":"Cancer","first-page":"1128","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman JM","year":"2015","unstructured":"Herman JM, Chang DT, Goodman KA, Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:1128\u20131137."},{"key":"B315","series-title":"Int J Radiat Oncol Biol Phys","first-page":"181","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg D","year":"2011","unstructured":"Schellenberg D, Kim J, Christman-Skieller C, Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;81:181\u2013188."},{"key":"B316","series-title":"J Clin Oncol","first-page":"326","article-title":"Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies","volume":"25","author":"Huguet F","year":"2007","unstructured":"Huguet F, Andre T, Hammel P, Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326\u2013331."},{"key":"B317","series-title":"Cancer","first-page":"47","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan S","year":"2007","unstructured":"Krishnan S, Rana V, Janjan NA, Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007;110:47\u201355."},{"key":"B318","series-title":"World J Gastroenterol","first-page":"2561","article-title":"Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study","volume":"9","author":"Bai YR","year":"2003","unstructured":"Bai YR, Wu GH, Guo WJ, Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study. World J Gastroenterol 2003;9:2561\u20132564."},{"key":"B319","series-title":"Strahlenther Onkol","first-page":"738","article-title":"Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort","volume":"189","author":"Combs SE","year":"2013","unstructured":"Combs SE, Habermehl D, Kessel K, Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 2013;189:738\u2013744."},{"key":"B320","series-title":"Int J Gastrointest Cancer","first-page":"123","article-title":"Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head","volume":"30","author":"Crane CH","year":"2001","unstructured":"Crane CH, Antolak JA, Rosen, II, Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001;30:123\u2013132."},{"key":"B321","series-title":"Med Phys","first-page":"521","article-title":"Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions","volume":"34","author":"Spalding AC","year":"2007","unstructured":"Spalding AC, Jee KW, Vineberg K, Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007;34:521\u2013529."},{"key":"B322","series-title":"Radiother Oncol","first-page":"117","article-title":"Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review","volume":"114","author":"Bittner MI","year":"2015","unstructured":"Bittner MI, Grosu AL, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer - a systematic review. Radiother Oncol 2015;114:117\u2013121."},{"key":"B323","series-title":"Int J Radiat Oncol Biol Phys","first-page":"158","article-title":"Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers","volume":"79","author":"Yovino S","year":"2011","unstructured":"Yovino S, Poppe M, Jabbour S, Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011;79:158\u2013162."},{"key":"B324","series-title":"Int J Radiat Oncol Biol Phys","first-page":"918","article-title":"NRG Oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford NN","year":"2025","unstructured":"Sanford NN, Narang AK, Aguilera TA, NRG Oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy. Int J Radiat Oncol Biol Phys 2025;121:918\u2013929."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e260046.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e260046.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/10\/article-e260046.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:40:28Z","timestamp":1791895228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/10\/article-e260046.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":324,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0046","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}